T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      PANCREATIC tumors; PROTEINS; T cells; IMMUNOTHERAPY; CHEMICAL inhibitors
    • Abstract:
      The author shares insight on T-cell immunotherapy against mutant Kirsten rat sarcoma virus (KRAS) for pancreatic cancer. The author discusses results of a research on the therapeutic use of autologous T cells transduced with two T-cell receptors (TCR) directed against the mutant KRAS molecule G12D expressed by the cancer cells in a 67-year old female. Emphasis is given on the need to explore potential failure mechanisms for T-cell therapy such as increased WNT-beta-catenin signaling.